Omid Hamid, MD

Articles

Dr. Hamid on the Differences in Evaluation Criteria for TIL Therapy in Melanoma

January 12th 2022

Omid Hamid, MD, discusses the differences in evaluation criteria for tumor-infiltrating lymphocytes therapy in melanoma.

Dr. Hamid on the Efficacy of TILs Following Immunotherapy in Advanced Melanoma

January 12th 2022

Omid Hamid, MD, discusses the efficacy of tumor-infiltrating lymphocyte therapy following immunotherapy in advanced melanoma.

Dr. Hamid on the Integration of TIL-Based Therapy Into Melanoma

September 30th 2021

Omid Hamid, MD, discusses the integration of tumor infiltrating lymphocyte–based therapy into the melanoma armamentarium.

Dr. Hamid on Promising Triplet Combinations Under Exploration in Melanoma

April 11th 2020

Omid Hamid, MD, discusses promising triplet combination under exploration in melanoma.

Collaboration Saves Lives: Managing irAEs is a "Dynamic Discussion"

January 16th 2020

Omid Hamid, MD, and Grace Cherry, NP, share the importance of multidisciplinary care for patients with melanoma, how to best manage immunotherapy-related adverse events, and tips for developing trusting relationships with patients so that they feel comfortable reporting toxicities.

Dr. Hamid on the FDA Approval of Pembrolizumab in Merkel Cell Carcinoma

December 20th 2018

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.

Dr. Hamid on the Inclusion of Patients With Brain Metastases on Melanoma Trials

December 1st 2018

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the inclusion of patients with brain metastases on melanoma clinical trials.

Dr. Hamid on the Effectiveness of Immunotherapy in AYA Patients With Melanoma

November 3rd 2018

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the effectiveness of immunotherapy in adolescent and young adult (AYA) patients with melanoma.

Dr. Hamid on a Retrospective Analysis of Pembrolizumab in Melanoma

October 30th 2018

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses a retrospective analysis of pembrolizumab (Keytruda) in patients with melanoma.

Dr. Hamid on Epacadostat Plus Pembrolizumab in Advanced Melanoma

September 11th 2017

Omid Hamid, MD, director of the melanoma center at the Angeles Clinic & Research Institute in Los Angeles, discusses the phase III results of the ECHO-202/KEYNOTE-037 trial, which explored the IDO inhibitor epacadostat plus pembrolizumab (Keytruda) in patients with advanced melanoma.

Dr. Hamid on Immunotherapy Approaches in Melanoma

December 22nd 2016

Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses different immunotherapy approaches that oncologists are currently exploring in melanoma.

Dr. Hamid on Promising Phase III Trials in Melanoma

December 16th 2016

Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses 2 exciting, ongoing phase III randomized trials in melanoma.

Dr. Omid Hamid on Vemurafenib and Atezolizumab in Melanoma

December 14th 2015

Omid Hamid, MD, Chief, Translational Research and Immunotherapy, Director, Melanoma Therapeutics, The Angeles Clinic, discusses a recent trial investigating the combination of vemurafenib and atezolizumab in melanoma in patients with previously untreated BRAF-positive unresectable or metastatic melanoma.

Dr. Hamid on Using Biomarkers for Immunotherapy in Melanoma

May 1st 2015

Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses the possibility of using biomarkers to select immunotherapy as a treatment option for patients with melanoma.

Advances in Immunotherapy for the Treatment of Non-Small Cell Lung Cancer

April 25th 2014

The treatment decisions for NSCLC are primarily dependent on the patient's performance status, extent of disease, and histological subtype. Significant developments in the area of targeted therapies have changed the treatment paradigm for NSCLC.

Dr. Hamid Discusses Melanoma Treatment

October 28th 2013

Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses the treatment of melanoma.

Dr. Hamid on Immune Therapy in Melanoma

October 8th 2013

Omid Hamid, MD, discusses using immune therapy to treat patients with melanoma.